Real-world Benefit of Apremilast Treatment of Patients With Moderate-to-severe Psoriasis After Transition From Fumaric Acid Esters

Trial Profile

Real-world Benefit of Apremilast Treatment of Patients With Moderate-to-severe Psoriasis After Transition From Fumaric Acid Esters

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs Apremilast (Primary) ; Fumarates
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms APART
  • Most Recent Events

    • 18 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 09 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top